Quarterly report pursuant to Section 13 or 15(d)

Dispositions - Additional Information (Details)

v3.19.3
Dispositions - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Nov. 04, 2015
Sep. 30, 2019
Sep. 30, 2019
Dec. 31, 2018
Asset Purchase Agreement and Ology Bioservices License Agreement [Member]        
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]        
Entitled to receive cash consideration       $ 4.6
Amount received from sale of discontinued operation   $ 0.5 $ 2.5  
Biodefense Business [Member]        
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]        
Royalties receivable percentage on net sales 15.00%